<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148564</url>
  </required_header>
  <id_info>
    <org_study_id>Energy</org_study_id>
    <nct_id>NCT00148564</nct_id>
  </id_info>
  <brief_title>Energy Homeostasis Under Treatment With Atypical Antipsychotics</brief_title>
  <official_title>Energy Homeostasis and Metabolism in Patients With Schizophrenic Disorders Under Treatment With Atypical Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of different atypical antipsychotics on
      weight changes, energy homeostasis, metabolism, energy intake as well as activity.

      Patients with schizophrenia or schizoaffective disorders will be randomly assigned to be
      treated with ziprasidone or olanzapine for 24 weeks.

      Primary outcome parameter are the weight changes after 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome parameter are the weight changes after 24 weeks between olanzapine and ziprasidone treatment</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in energy homeostasis, food intake, metabolism</measure>
    <time_frame>during and after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zpirasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>treatment with either Olanzapine or Ziprasidone</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>treatment with either Olanzapine or Ziprasidone</description>
    <arm_group_label>Zpirasidone</arm_group_label>
    <other_name>Zeldox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or related disorders(DSM-IV)

          -  Indication for long-term treatment with antipsychotics

          -  BMI between 20 to 30

          -  Weight changes less than 3kg in the last 3 months before inclusion

          -  Informed consent

        Exclusion Criteria:

          -  Psychiatric comorbidity

          -  Depot antipsychotic in the last 2 months

          -  Antipsychotics in the last 2 weeks

          -  Treatment with olanzapine, clozapine or ziprasidone in teh last 3 months

          -  Treatment with drugs, that may lead to weight changes

          -  Significant endocrine, neurological, cardiovascular, hepatic, renal, metabolic, or
             other medical diseases or any clinically relevant abnormalities in laboratory tests

          -  Female subjects during pregnancy and breastfeeding

          -  Female subjects within childbearing years who were not using adequate birth control

          -  Patients who are judged by the investigator to be at serious suicide risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Campus Mitte; Dept. of Psychiatry and Psychotherapy and Department of Psychiatry, Kliniken Essen-Mitte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>September 26, 2008</last_update_submitted>
  <last_update_submitted_qc>September 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Martin Schaefer, MD</name_title>
    <organization>Charite University, Berlin, Germany</organization>
  </responsible_party>
  <keyword>weight gain</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>atypical antipsychotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

